Basic information
- CAS
8771-40-2- Standard SMILES
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I- InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N- Molecular formula
- C18H24I3N3O9
- Average molar mass
- 807.1 g/mol
- Monoisotopic mass
- 806.8647
Overview
Ioversol is an amidobenzoic acid.
Names & identifiers
- Preferred name
- Ioversol
- IUPAC
- 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
- English name
- Ioversol
- Molecular formula
- C18H24I3N3O9
- Molecular weight
- 807.11
Names & synonyms
ioversol87771-40-2OptirayMP-328Optiray 320IoversolumOptiray 160Optiray 240Optiray 300Optiray 350DTXSID2045521MP 328
Show more names
LoversolP 530oversolIodofolIodophorolIoversol API
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-N3RIB7X24KN,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamideDTXCID0025521N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamideioversoloN1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57669
Database identifiers
- CAS
8771-40-2、87771-40-2- PubChem CID
- 3741
- DTXSID
DTXSID2045521- ChEMBL
CHEMBL1200614- ChEBI
CHEBI:31717- UNII
- N3RIB7X24K
- EC Number
Properties
Computed structural properties
- XLogP
- -3
- Topological polar surface area
- 200 Ų
- Hydrogen bond donors
- 8
- Hydrogen bond acceptors
- 9
- Rotatable bonds
- 12
- Heavy atoms
- 33
- Formal charge
- 0
- Complexity
- 623
Experimental & physicochemical properties
DrugsPharmaceuticals
LogP-2.98
SolubilityWater soluble
Human Drugs
Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Melting Point180-182°C
Collision Cross Section216.25 Ų [M+H]+
Physicochemical properties
- Melting point
- 180 · 180-182°C
- Boiling point
- 864.9 · 864.9±65.0 °C(Predicted)
- Density
- 37 · d37 1.371 (c = 320 mgI/ml)
- storage temp.
- Refrigerator
- solubility
- DMSO (Sparingly), Methanol (Slightly)
- pka
- 11.34 · 11.34±0.46(Predicted)
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ioversol
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Safety data
- wgk
- WGK 3
- hs_code
- 2924296000
- Toxicity
- LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)
- Storage Class
- 11 - Combustible Solids
Chemistry & industry
Pharmacology
ATC Code
V08AB07
V - Various
QV - Various
Protein BindingIoversol does not bind to serum or plasma proteins.
Pharmacodynamics
The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary. The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool. For angiographies, the maximum contrast enhancement of ioversol occurs almost immediately (15-120 seconds). Following rapid intravenous injection, ioversol can be visualized in the renal parenchyma within 30 to 60 seconds. In patients with normal renal function, opacification of the calyces and pelves takes place within 1-3 minutes, with an optimum contrast within 5-15 minutes.
Mechanism of Action
Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.
Biological Half-LifeThe elimination half-life was 1.5 hr in healthy volunteers (n=12) receiving 50 and 150 mL of ioversol 68%. In patients with renal dysfunction, the elimination half-life of ioversol is prolonged.
Related reactions
3 records
Compound notes
Loading…